You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Data Presented at the American Urological Association 2019 Annual Meeting - CHICAGO, May 5, 2019 /PRNewswire/ -- Astellas Pharma Inc. today announced results from the Phase 4, 12-week PLUS...
April 25, 2019 -- Astellas and the U.S. Department of Justice (DOJ) have reached an agreement to resolve all claims raised by the government in its investigation regarding Astellas’ past...
NORTHBROOK, Ill., April 3, 2019 /PRNewswire/ -- Astellas is pleased to announce two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. Steven...
NORTHBROOK, Ill., March 28, 2019 /PRNewswire/ -- For the fifth consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation's (HRC) annual Corporate Equality...
Read more about Astellas: Five Consecutive Years of Perfect Equality Scores
NORTHBROOK, Ill., March 18, 2019 /PRNewswire/ -- Astellas announced today that PROGRAF® Granules (tacrolimus for oral suspension) is now available for prescription in the United States. PROGRAF...
Follow U.S. news
